ArticleMolecular plant pathology2026
The Tomato Transcription Factor RAV Affects the Systemic Infection of TYLCV by Interacting With V2.
Article in Molecular plant pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Tomato yellow leaf curl virus (TYLCV) is a widely distributed pathogen responsible for tomato yellow leaf curl disease. However, the molecular mechanism underlying TYLCV infection and the plant antivirus pathway remains unclear. This study reports that tomato (Solanum lycopersicum) RELATED TO ABSCISIC ACID INSENSITIVE3/VIVIPAROUS2 (SlRAV2), a transcription factor of the APETALA2/ETHYLENE RESPONSE FACTOR (AP2/ERF) superfamily containing an AP2/B3 DNA-binding domain, suppresses systemic TYLCV accumulation by interacting with the V2 protein, an RNA silencing suppressor (RSS) encoded by TYLCV. Transient overexpression and silencing of SlRAV2 altered TYLCV levels in systemic leaves, prompting us to investigate the underlying mechanism. Molecular analyses revealed that SlRAV2 directly binds to the promoter of the pathogenesis-related protein 1 (SlPR1) gene, thereby activating its expression and contributing to basal defence responses. V2 affects the nuclear import of SlRAV2 through protein-protein interaction and recruits SlRAV2 to bind more 21-nt double-stranded siRNA, thereby enhancing its own RSS activity and transiently increasing local TYLCV accumulation. Moreover, nuclear-localised V2 increases SlRAV2 binding affinity for the SlPR1 promoter, resulting in elevated SlPR1 transcription and concomitant accumulation of reactive oxygen species (ROS). Our findings reveal a novel antiviral mechanism whereby SlRAV2 interacts with V2 to enhance the local accumulation of TYLCV transiently, causing localised cell necrosis and preventing viral spread from infiltrated leaves to systemic leaves, thereby suppressing the systemic infection of TYLCV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.